Lilly selects Cogstate as preferred provider for Alzheimer Disease Platform

Cogstate Ltd announced that Eli Lilly’s has selected Cogstate as preferred provider for Alzheimer’s Disease Platform, to support with solutions to ensure high-quality neuropsychological outcome measures in clinical trials. Cogstate and Lilly will deploy an innovative program to improve the way that research sites train and collect endpoint data across Lilly’s portfolio of Alzheimer’s disease studies.

Cogstate has brought together scientific experts with learning experts to create a novel, integrated program that drives efficiencies in rater training and certification, electronic clinical outcome assessment (eCOA) data capture, and risk-based central monitoring.

Cogstate CEO, George Hunnewell said that they are excited to partner with Lilly to realize their vision for a portfolio-wide approach to endpoint quality assurance that reduces cycle times and lessens the burden on research sites. By more efficiently and effectively preparing sites to administer neuropsychological assessments across all of Lilly’s Alzheimer’s studies, they dramatically improve the research experience for clinicians and patients while also ensuring greater reliability of the outcome measures.